Zomedica - רווח נקי למניה ב-12 החודשים האחרונים ZOM

Zomedica Corp. attracts leading bioengineers through high R&D investment and a commitment to personnel development. The 12-month YoY earnings per share growth rate helps assess real revenue dynamics, where 15.20 expresses the latest level of this metric. A positive image among private investors and clinics is complemented by the synergy between Truforma and PulseVet systems, which creates an efficient environment for veterinarians.
ZOM (Zomedica Corporation): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Effective asset selection requires an analysis of net income stability on a per-share basis. This metric measures the annual change in EPS (TTM), reflecting the business's profitability dynamics relative to the previous year. For Zomedica Corp. (ZOM), this indicator demonstrates how sales of veterinary rapid analyzers and consumables convert into shareholder returns. Analyzing the current EPS TTM YoY growth rate allows for an assessment of the company's sensitivity to market demand. Sharp fluctuations in the trend line signal a shift in the business's fundamental value.